Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10840679 | 0.80 | MEN1 (0.50) | HTR2AHTR2CHTR2B | |
| SCHEMBL30163317 | 0.80 | MEN1 (0.50) | HTR2AHTR2CHTR2B | |
| SCHEMBL15237774 | 0.80 | CHRM3 (0.39) | CHRM3CHRM2CHRM1DRD2HTR1A | |
| SCHEMBL10841161 | 0.79 | ALDH1A1 (0.39) | DRD2HTR1ADRD3 | |
| SCHEMBL9394752 | 0.79 | CD44 (0.36) | DRD2DRD3 | |
| SCHEMBL10841078 | 0.79 | HTR2C (0.41) | HTR1AHTR2CHTR2B | |
| SCHEMBL19511078 | 0.78 | ALDH1A1 (0.35) | — | |
| SCHEMBL18602431 | 0.76 | HTR1A (0.40) | HTR1A | |
| SCHEMBL10840744 | 0.76 | PDK2 (0.39) | DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11422593 | 0.76 | DRD2 (0.46) | CHRM3CHRM2CHRM1DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | claimed |
| WO-2009024095-A1 | METHOD OF MAKING AND ADMINISTERING QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-02-26 | — | — | WO | claimed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | claimed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012083866-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| EP-1109235-B1 | Organic electroluminescence device | SAMSUNG SDI CO LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| EP-0867432-B1 | Fused N-heterocyclic compounds substituted with benzyloxy, process for their preparation and their use as bradykinin receptor antagonists | AVENTIS PHARMA GMBH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6211196-B1 | 8-BENZYLOXY-(TETRAHYDRO)QUINOLINE DERIVATIVES; LIVER CIRRHOSIS, ALZHEIMER*S DISEASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
| EP-0867432-A2 | Fused N-heterocyclic compounds substituted with benzyloxy, process for their preparation and their use as bradykinin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HKDC1, HK1 | CHRM3 3838/4885CHRM2 4248/4885CHRM1 3691/4885 |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | CHRM3 3401/4885CHRM2 3880/4885CHRM1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.